{"gene":"FGF5","run_date":"2026-06-09T23:54:43","timeline":{"discoveries":[{"year":1994,"finding":"FGF5 functions as an inhibitor of hair elongation and regulator of the anagen-to-catagen transition in the hair growth cycle. Mice homozygous for a targeted null allele (fgf5neo) or the spontaneous angora (go) mutation — shown to be a deletion in Fgf5 exon 1 — display abnormally long hair. FGF5 mRNA is expressed in the outer root sheath of hair follicles specifically during anagen VI.","method":"Gene targeting in ES cells (null allele), complementation test with spontaneous mutant (go), RNA in situ hybridization in wild-type hair follicles","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — genetic null + spontaneous mutant complementation + spatial expression, replicated by multiple independent mutant alleles","pmids":["7923352"],"is_preprint":false},{"year":1988,"finding":"FGF5 encodes a secreted protein with ~40–50% amino acid homology to acidic and basic FGFs across two conserved regions (122 of 267 residues), sharing the three-exon gene structure typical of the FGF family. FGF5 transforming activity was activated by juxtaposition of a retroviral transcriptional enhancer upstream of the native promoter during transfection.","method":"cDNA cloning, sequence homology analysis, NIH 3T3 transformation assay, structural genomic analysis","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — direct sequencing and in vitro transformation assay establishing protein identity and activating rearrangement mechanism","pmids":["3211147"],"is_preprint":false},{"year":1998,"finding":"An alternatively spliced FGF5 mRNA (FGF5S), lacking exon 2, encodes a 121–123 amino acid truncated protein. FGF5S acts as a partial agonist/antagonist of FGF5: it binds FGFR1, partially inhibits FGF5-induced FGFR1 tyrosine phosphorylation and downstream signaling, and at high concentrations partially antagonizes FGF5-induced PC12 cell differentiation, while exerting very weak neurotrophic activity alone.","method":"cDNA cloning, RT-PCR, genomic analysis, PC12 cell differentiation assays, FGFR1 tyrosine phosphorylation assay, competitive binding to FGFR1","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — receptor binding, phosphorylation assay, and functional differentiation assay in single study with multiple orthogonal methods","pmids":["9786939"],"is_preprint":false},{"year":1996,"finding":"Rat FGF5 alternative splicing generates a short-form mRNA (FGF5S) by exclusion of exon 2, encoding a 121-amino acid truncated protein whose N-terminal 117 residues are identical to those of full-length FGF5. Both FGF5 and FGF5S mRNAs are expressed in embryo and adult brain.","method":"cDNA cloning, RT-PCR, genomic exon mapping","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cDNA cloning with genomic structure confirmation, single lab, two methods (RT-PCR + genomic sequencing)","pmids":["8611621"],"is_preprint":false},{"year":2000,"finding":"FGF5 (full-length) induces catagen and inhibits hair growth during anagen when injected subcutaneously in depilated mice. FGF5S alone has no effect on hair growth but significantly inhibits the catagen-promoting activity of FGF5 when co-injected, indicating dual-mode regulation of the hair cycle by the two Fgf5 gene products.","method":"Subcutaneous injection of recombinant FGF5 and FGF5S proteins into depilated mice; histological analysis of hair follicle stage","journal":"The Journal of investigative dermatology","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo protein injection with defined phenotypic readout, consistent with mechanism proposed by genetic studies","pmids":["10692103"],"is_preprint":false},{"year":1998,"finding":"In rat skin, FGF5 protein localizes to macrophage-like cells in the dermis (density correlated with hair cycle phase), while FGF5S protein localizes specifically to hair follicles (high in early anagen VI, decreasing in catagen), suggesting distinct compartmentalization of the two Fgf5 gene products during the hair cycle.","method":"Immunohistochemistry with isoform-specific monoclonal antibodies (E723 for FGF5 long-form; B2B6 for both forms) on rat skin sections at defined hair cycle stages","journal":"The Journal of investigative dermatology","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — isoform-specific antibody immunohistochemistry across hair cycle stages, single lab, two antibody probes","pmids":["9856803"],"is_preprint":false},{"year":1998,"finding":"FGF5 is secreted vectorially from the basolateral surface of polarized RPE (ARPE-19) cells: >90% of total secreted FGF5 accumulates in basolateral media over 6 hours, as determined by immunoblot of conditioned media from adenovirus-transduced polarized monolayers.","method":"Adenovirus-mediated FGF5 gene transfer into polarized ARPE-19 monolayers; domain-selective collection and immunoblot analysis of conditioned apical vs. basolateral media","journal":"Investigative ophthalmology & visual science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct secretion polarity assay with quantitative immunoblot, single lab, single method","pmids":["9856785"],"is_preprint":false},{"year":2001,"finding":"FGF5-induced mitogenesis in pancreatic ductal cells is mediated specifically through the IIIc splice variant of FGFR1 via the MAPK pathway: TAKA-1 cells that do not express FGFR1 are unresponsive to FGF5, but TAKA-1 clones stably expressing FGFR-1 IIIc show growth stimulation and enhanced MAPK activity in response to FGF5; the MEK inhibitor PD98059 blocks this effect.","method":"Stable transfection of FGFR-1 IIIc cDNA into TAKA-1 cells; cell proliferation assay; MAPK activity assay; MEK inhibitor (PD98059) treatment","journal":"International journal of pancreatology","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — gain-of-function receptor expression, proliferation assay, pathway inhibitor, multiple orthogonal methods in single study","pmids":["11876253"],"is_preprint":false},{"year":2001,"finding":"Denervated Schwann cells upregulate FGF5 mRNA and protein following axotomy; axon-Schwann cell contact suppresses FGF5 expression in regenerating sciatic nerve; forskolin also diminishes FGF5 mRNA in cultured Schwann cells, indicating that axon-Schwann cell interactions negatively regulate FGF5 expression.","method":"cDNA array screening, Northern blotting, in situ hybridization, Western blotting of axotomized rat sciatic nerve; cultured Schwann cells treated with forskolin","journal":"Journal of neuroscience research","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — multiple validation methods (Northern, ISH, Western) in single lab for expression regulation, functional context established","pmids":["11598998"],"is_preprint":false},{"year":2003,"finding":"FGF-5 (together with FGF-2) regulates astroglial differentiation in vivo: FGF-5-/- mice show region-specific reduction in GFAP in midbrain tegmentum astrocytes. In FGF-2-/-/FGF-5-/- double mutant mice, GFAP is reduced in cortex, striatum, and midbrain, intermediate filaments in perivascular endfeet are decreased, and blood-brain barrier permeability is enhanced (albumin extravasation; reduced Occludin and ZO-1 levels).","method":"Single and double mutant mouse analysis; GFAP and S100 immunostaining; electron microscopy of perivascular endfeet; albumin extravasation assay; tight junction protein (Occludin, ZO-1) immunoblot; cortical astrocyte cultures with exogenous FGF rescue","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis with single and double knockouts, multiple orthogonal methods, functional rescue experiment","pmids":["12878680"],"is_preprint":false},{"year":2003,"finding":"A decapeptide (P3: 95-VGIGFHLQIY-104) corresponding to a receptor-binding region of FGF5 suppresses FGF5-induced proliferation of fibroblasts and FGFR-1c-expressing Ba/F3 cells in vitro, partially inhibits FGF5 binding to FGFR-1(IIIc)/Fc chimera, and reduces FGF5-induced inhibition of hair follicle growth and cell proliferation in vivo.","method":"Peptide synthesis; cell proliferation assay (BALB/3T3, NIH/3T3, FGFR-1c Ba/F3); competitive receptor-binding assay (FGFR-1(IIIc)/Fc chimera); in vivo depilated mouse model; anti-Ki67 staining of hair follicles","journal":"Journal of cellular physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — receptor binding competition plus cellular and in vivo functional assays, single lab","pmids":["14502567"],"is_preprint":false},{"year":2005,"finding":"Adenoviral overexpression of FGF-5 in hibernating swine myocardium improves wall thickening, induces profound myocyte cellular hypertrophy, and causes a 7-fold increase in Ki-67-positive myocytes and increased phospho-histone H3-positive myocytes, demonstrating that FGF-5 directly stimulates hypertrophy and myocyte cell cycle re-entry rather than angiogenesis in cardiac muscle.","method":"Intracoronary injection of replication-deficient AdvFGF-5 in swine; echocardiographic wall-thickening measurement; histological myocyte diameter measurement; Ki-67 and phospho-histone H3 immunostaining; flow measurement","journal":"Circulation research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo gain-of-function with multiple histological readouts, single lab, large animal model","pmids":["15761196"],"is_preprint":false},{"year":2008,"finding":"FGF5 promotes GBM cell proliferation and survival via autocrine/paracrine signaling through FGFR1 IIIc: siRNA-mediated FGF5 knockdown reduces proliferation and increases apoptosis; recombinant FGF5 promotes proliferation and prevents apoptosis; dominant-negative FGFR1 IIIc or pharmacological FGFR inhibitors block these effects. FGF5 also stimulates HUVEC proliferation, migration, and tube formation (paracrine angiogenic effect).","method":"siRNA knockdown; recombinant FGF5 treatment; dominant-negative FGFR1 IIIc expression; pharmacological FGFR inhibitors; cell proliferation, apoptosis, migration assays; HUVEC tube formation assay","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (siRNA, dominant-negative, inhibitor, recombinant protein) in single study establishing autocrine FGFR1 IIIc signaling","pmids":["18362893"],"is_preprint":false},{"year":2014,"finding":"Loss-of-function mutations in human FGF5 cause trichomegaly (extreme eyelash growth) inherited in an autosomal recessive pattern. Hair follicle organ culture experiments show that exogenous FGF5 protein induces regression of the human hair follicle, confirming FGF5 as a direct inducer of follicle catagen in humans.","method":"Whole exome sequencing and homozygosity mapping in trichomegaly families; hair follicle organ culture with recombinant FGF5; anagen:telogen ratio measurement","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — human genetics plus direct organ culture functional assay, replication across multiple families","pmids":["24989505"],"is_preprint":false},{"year":2015,"finding":"In cashmere goat dermal papilla cells, FGF5 overexpression upregulates IGF-1, versican, and noggin mRNA (anagen maintenance factors) and downregulates BMP4 (catagen signal); FGF5S overexpression partially reverses these effects, demonstrating FGF5S acts as an inhibitor of FGF5 function in dermal papilla cells.","method":"Adenovirus-mediated overexpression of FGF5 and FGF5S in isolated primary/secondary hair follicle dermal papilla cells; qPCR for downstream gene expression; FGFR1 expression confirmed by immunostaining","journal":"Gene","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — adenoviral gain-of-function with downstream gene readouts, single lab, consistent with prior mechanistic data","pmids":["26390813"],"is_preprint":false},{"year":2019,"finding":"FGF5 promotes osteosarcoma cell proliferation through activation of the MAPK signaling pathway: CRISPR/Cas9 knockout of FGF5 reduces MAPK pathway protein levels and inhibits proliferation; recombinant FGF5 addition restores MAPK activity and promotes proliferation while inhibiting apoptosis.","method":"CRISPR/Cas9 FGF5 knockout; recombinant FGF5 treatment; Western blot for MAPK pathway proteins; CCK-8 proliferation assay; xenograft nude mouse model","journal":"Cancer management and research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO and recombinant protein rescue with pathway readout, single lab, in vitro and in vivo","pmids":["31372048"],"is_preprint":false},{"year":2020,"finding":"FGF5 inhibits ERK1/2 MAPK activity in Schwann cells while promoting rapid Schwann cell migration and adhesion via upregulation of N-cadherin. FGF5 is strongly upregulated in Schwann cells of the distal mouse sciatic nerve following injury; FGFR1 and FGFR2 are the predominant FGF5 receptors expressed in peripheral nerve Schwann cells.","method":"Microarray and mRNA sequencing of injured sciatic nerve; RT-PCR, qPCR, Western blotting, immunostaining; recombinant FGF5 treatment of primary rat Schwann cells; ERK1/2 phosphorylation assay; migration assay; N-cadherin expression assay","journal":"Frontiers in cellular neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (expression profiling, Western, migration assay, ERK assay), single lab","pmids":["32848626"],"is_preprint":false},{"year":2020,"finding":"In FGF5-knockout sheep, the downstream signaling cascade of FGF5 involves FGFR1 → androgen/AR → Wnt/β-catenin → Shh/Gli2 → c-MYC → keratins, and crosstalk between androgen and Wnt/β-catenin signaling contributes to increased fine-wool and active hair-follicle density when FGF5 is absent.","method":"CRISPR/Cas9 FGF5 KO in Dorper sheep; qPCR for FGF5 mRNA; H&E and immunohistochemistry; Western blot for pathway components; pathway inhibitor/activator experiments","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO with pathway analysis using multiple methods, single lab","pmids":["32472005"],"is_preprint":false},{"year":2021,"finding":"RNA aptamers selected against human FGF5 bind FGF5 with high affinity and specificity (Kd = 0.7 nM for F5f1; Kd = 0.118 nM for truncated F5f1_56) and inhibit FGF5-induced cell proliferation without inhibiting FGF2-induced proliferation, establishing that FGF5 receptor-binding activity drives its mitogenic effect.","method":"SELEX (aptamer selection); surface plasmon resonance binding assay; FGF5-induced cell proliferation inhibition assay; cross-reactivity testing with FGF1, FGF2, FGF4, FGF6, FGFR1","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 1–2 / Moderate — in vitro binding (SPR) and functional cell proliferation assay, single lab, two orthogonal methods","pmids":["33536494"],"is_preprint":false},{"year":1998,"finding":"FGF5 gene expression in differentiated RPE cells is controlled by a proximal promoter/enhancer active between sequences -314 and +48 (not cell-context dependent), and a silencer element (-1256/-883) active only in differentiated RPE cells. Specific nuclear proteins from differentiated (but not proliferating) RPE cells bind to two small distal promoter regions (-1195/-1173 and -984/-967), suggesting differentiation-specific transcriptional repression of FGF5.","method":"Transient transfection of FGF5 promoter/luciferase deletion constructs in proliferating vs. differentiated RPE cells; gel mobility shift assays with differentiated/proliferating nuclear extracts","journal":"Experimental eye research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — promoter deletion analysis plus EMSA for protein binding, single lab, two orthogonal methods","pmids":["9733582"],"is_preprint":false},{"year":2022,"finding":"FGF5 overexpression in cardiomyocytes reduces LPS-induced pyroptosis and oxidative stress by inhibiting CaMKII/NFκB signaling: FGF5 overexpression decreases p-CaMKII, p-NFκB, NLRP3, caspase-1, IL-1β and IL-18 levels; the CaMKII inhibitor KN93 recapitulates FGF5's protective effects.","method":"Adenovirus-mediated FGF5 overexpression in vivo (mouse LPS model) and in vitro (cardiomyocytes); echocardiography; Western blot for CaMKII, NFκB, NLRP3, caspase-1, IL-1β, IL-18; KN93 pharmacological inhibition","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo and in vitro gain-of-function plus pharmacological inhibitor validation, single lab","pmids":["36368152"],"is_preprint":false},{"year":2022,"finding":"FGF5 overexpression protects endothelial cells from LPS-induced pyroptosis via activation of AKT signaling: FGF5 overexpression activates AKT, and the AKT inhibitor MK2206 abolishes FGF5's protective effect in HUVECs exposed to LPS.","method":"FGF5 overexpression in mouse ALI model and HUVECs; pyroptosis assay; Western blot for AKT; pharmacological inhibition with MK2206","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro/in vivo gain-of-function with pathway inhibitor rescue, single lab","pmids":["36244113"],"is_preprint":false},{"year":2019,"finding":"FGF5 promoter methylation in esophageal squamous cell carcinoma represses FGF5 expression. Cisplatin treatment induces FGF5 expression in unmethylated cell lines but not methylated ones; exogenous FGF5 overexpression in a methylated cell line confers resistance to cisplatin, indicating FGF5 expression modulates chemotherapy response.","method":"Bisulfite pyrosequencing for methylation; qPCR/Western blot for FGF5 expression; cisplatin treatment of cell lines with varying methylation status; FGF5 overexpression in methylated cell line; clonogenic survival assay","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — methylation-expression correlation confirmed by functional overexpression experiment, single lab, multiple methods","pmids":["31527639"],"is_preprint":false},{"year":2016,"finding":"FGF2 and FGF5 intrinsic to human aortic endothelial cells (HAECs) promote angiogenesis: siRNA knockdown of FGF2 and FGF5 significantly attenuates VEGF-A-stimulated vascular sprouting from HAECs (but less so from HUVECs), demonstrating an autocrine/paracrine angiogenic role for FGF5 in aortic endothelial cells.","method":"3D microfluidic angiogenesis system; siRNA knockdown of FGF2 and FGF5 in HAECs and HUVECs; quantification of vascular sprouting; qPCR for FGF2/FGF5 expression","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional RNAi knockdown in 3D system with phenotypic quantification, single lab","pmids":["27357248"],"is_preprint":false},{"year":2000,"finding":"FGF5 misexpression in the developing chick limb (via RCAS retroviral vector) severely inhibits mature myocyte formation (reduced MyoD and myosin heavy chain expression) and simultaneously stimulates proliferation and expansion of tenascin-expressing connective tissue fibroblasts and perichondrial cells, as measured by BrdU incorporation.","method":"RCAS retroviral overexpression of human FGF5 in chick embryo hindlimb; immunostaining for MyoD, myosin heavy chain, tenascin; BrdU pulse labeling for proliferation; histological analysis","journal":"Developmental dynamics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo gain-of-function with multiple immunostaining and proliferation readouts, single lab","pmids":["11066093"],"is_preprint":false},{"year":2001,"finding":"Adeno-associated virus-mediated FGF-5 delivery to the subretinal space of P23H and S334ter transgenic rats rescues photoreceptors from cell death. Post-injection, FGF-5 protein localizes to inner and outer segments of photoreceptors, and FGFR1 and FGFR2 are upregulated in these regions, suggesting rescue is mediated by receptor tyrosine kinase signaling in photoreceptors.","method":"Subretinal AAV injection; morphological and ERG functional analysis; immunocytochemistry for FGF-5, FGFR1, FGFR2 localization","journal":"Molecular therapy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo gene delivery with functional and morphological rescue plus receptor localization, single lab","pmids":["11319911"],"is_preprint":false},{"year":2017,"finding":"FGF5 overexpression in human melanoma cells increases clonogenicity and invasion (but not short-term growth) in vitro, and enhances tumor growth, proliferation index, and angiogenesis in vivo. These effects are associated with increased signaling along the MAPK and NFAT axes but no effect on STAT3 signaling. Silencing FGF5 in high-FGF5 melanoma cells has opposite effects.","method":"FGF5 overexpression and siRNA silencing in melanoma cell lines; clonogenicity and invasion assays; xenograft in vivo model; Ki-67 and apoptosis assays; signaling pathway Western blots; tissue microarray immunohistochemistry","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — bidirectional manipulation (OE + KD) with multiple functional readouts and pathway analysis, single lab","pmids":["29152117"],"is_preprint":false},{"year":2024,"finding":"FGF5 editing in sheep decreases cortisol concentration in skin, activates antioxidant enzyme GSH-Px, and modulates Wnt signaling pathway components (Rspondins as agonists, Notum as antagonist) in hair follicle regeneration, promoting secondary hair follicle development and fine wool growth.","method":"CRISPR/Cas9 FGF5 editing in Dorper sheep; cortisol measurement; GSH-Px activity assay; qPCR and Western blot for Wnt pathway components; histological analysis of hair follicle density","journal":"Cells","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo genetic KO with multiple molecular pathway readouts, single lab","pmids":["38891117"],"is_preprint":false},{"year":2024,"finding":"FGF5 knockout (combined with MSTN Del73C mutation) in sheep activates FOSL1 via the MEK-ERK-FOSL1 axis; activated FOSL1 promotes skeletal muscle satellite cell proliferation and inhibits myogenic differentiation by suppressing MyoD1 expression, resulting in smaller myotubes; activated ERK1/2 also inhibits secondary myotube fusion via Ca2+-dependent CaMKII activation.","method":"CRISPR/Cas9 dual-gene edited sheep (MSTN Del73C + FGF5 KO); Western blot for MEK-ERK-FOSL1 pathway; MyoD1 expression analysis; myotube morphology; CaMKII pathway analysis; F0 and F1 phenotyping","journal":"eLife","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo genetic model with multiple downstream pathway readouts, though FGF5 and MSTN effects are confounded by dual-gene editing","pmids":["39365728"],"is_preprint":false},{"year":2025,"finding":"FGF5 overexpression suppresses ferroptosis in renal tubular epithelial cells subjected to ischemia-reperfusion-like injury by activating mitophagy, reducing oxidative stress and inflammatory responses.","method":"FGF5 overexpression in NRK-52E and HK-2 cells; cell viability assay; oxidative stress markers; inflammatory cytokine assay; mitophagy assessment; ferroptosis markers","journal":"Journal of molecular histology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, in vitro only, mechanistic link between FGF5, mitophagy, and ferroptosis established by overexpression alone without definitive mechanistic dissection","pmids":["40913740"],"is_preprint":false},{"year":1990,"finding":"The FGF5 oncogene was mapped to human chromosome 4 by PCR-based somatic cell hybrid analysis.","method":"PCR amplification of FGF5 sequences from somatic cell hybrid DNAs containing defined human chromosomes","journal":"BioTechniques","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct PCR-based chromosomal assignment, clear single-method result","pmids":["2317376"],"is_preprint":false}],"current_model":"FGF5 is a secreted signaling protein that acts as a negative regulator of the mammalian hair growth cycle by inhibiting anagen progression and inducing the anagen-to-catagen transition via its predominant high-affinity receptor FGFR1 IIIc, which activates MAPK signaling; its alternatively spliced short form (FGF5S) functions as a partial antagonist that competes for FGFR1 binding and suppresses FGF5-induced catagen; beyond hair follicles, FGF5 also regulates astroglial differentiation and blood-brain barrier integrity, promotes Schwann cell migration and adhesion via N-cadherin upregulation while inhibiting ERK activity, stimulates cardiac myocyte hypertrophy and cell cycle re-entry, and exerts pro-tumorigenic autocrine/paracrine effects through MAPK and NFAT signaling in glioblastoma and melanoma."},"narrative":{"mechanistic_narrative":"FGF5 is a secreted member of the fibroblast growth factor family that acts as a key negative regulator of the mammalian hair growth cycle, inhibiting hair elongation and driving the anagen-to-catagen transition [PMID:7923352, PMID:3211147]. Genetic loss of Fgf5 in mice (null allele and the spontaneous angora mutation) and recessive loss-of-function mutations in human FGF5 (causing trichomegaly) produce abnormally long hair, while exogenous FGF5 induces follicle regression in human and mouse follicle organ culture and depilated-skin models, establishing FGF5 as a direct catagen inducer [PMID:7923352, PMID:10692103, PMID:24989505]. FGF5 signals predominantly through the IIIc splice variant of FGFR1, activating the MAPK/MEK-ERK pathway to drive proliferation; gain-of-function receptor expression, dominant-negative FGFR1 IIIc, FGFR/MEK inhibitors, and FGF5-specific RNA aptamers all converge on receptor-binding-dependent mitogenesis [PMID:11876253, PMID:18362893, PMID:33536494]. An alternatively spliced short form, FGF5S, which lacks exon 2, binds FGFR1 and acts as a partial antagonist: it suppresses FGF5-induced receptor tyrosine phosphorylation, blocks FGF5's catagen-promoting activity in vivo, and reverses FGF5-driven changes in dermal papilla anagen/catagen gene programs (IGF-1, versican, noggin, BMP4) [PMID:9786939, PMID:10692103, PMID:26390813]. In the absence of FGF5, hair-follicle programs are de-repressed through an FGFR1→androgen/AR→Wnt/β-catenin→Shh/Gli2→c-MYC→keratin cascade, promoting secondary follicle density and fine-wool growth [PMID:32472005, PMID:38891117]. Beyond the follicle, FGF5 exerts mitogenic and pro-survival autocrine/paracrine effects in glioblastoma, melanoma, and osteosarcoma via MAPK (and NFAT) signaling [PMID:18362893, PMID:31372048, PMID:29152117], regulates astroglial GFAP expression and blood-brain-barrier integrity [PMID:12878680], promotes Schwann cell migration and adhesion via N-cadherin while inhibiting ERK [PMID:32848626], and drives cardiac myocyte hypertrophy and cell-cycle re-entry [PMID:15761196].","teleology":[{"year":1988,"claim":"Establishing that FGF5 is a bona fide secreted FGF-family protein with transforming potential defined its molecular identity and oncogenic capacity.","evidence":"cDNA cloning, sequence homology analysis, and NIH 3T3 transformation assay","pmids":["3211147"],"confidence":"High","gaps":["Receptor and physiological function not yet defined","Mechanism of transformation beyond enhancer-driven overexpression not characterized"]},{"year":1990,"claim":"Mapping FGF5 to human chromosome 4 anchored the gene physically, enabling later genetic disease association.","evidence":"PCR-based somatic cell hybrid chromosomal assignment","pmids":["2317376"],"confidence":"Medium","gaps":["No functional consequence established","No disease locus linkage at this stage"]},{"year":1994,"claim":"Loss-of-function genetics answered what FGF5 does physiologically, revealing it as an inhibitor of hair elongation that controls the anagen-to-catagen transition.","evidence":"Gene targeting (null allele), complementation with the spontaneous angora mutant, and in situ hybridization in hair follicles","pmids":["7923352"],"confidence":"High","gaps":["Receptor mediating the effect not identified","Downstream signaling in follicle not defined","Source cell type of active FGF5 unclear"]},{"year":1998,"claim":"Discovery and characterization of the exon-2-skipped short form FGF5S established a built-in antagonistic regulator that competes for FGFR1 and dampens FGF5 signaling.","evidence":"cDNA cloning, RT-PCR, FGFR1 competitive binding, tyrosine phosphorylation assay, and PC12 differentiation assay; isoform-specific immunohistochemistry localized the two products to distinct skin compartments","pmids":["9786939","8611621","9856803"],"confidence":"High","gaps":["Structural basis of partial antagonism not resolved","Relative in vivo abundance and regulation of splicing not quantified"]},{"year":1998,"claim":"Secretion polarity and promoter dissection addressed how FGF5 production and trafficking are regulated, showing basolateral vectorial secretion and differentiation-specific transcriptional repression.","evidence":"Polarized ARPE-19 conditioned-media immunoblot; FGF5 promoter/luciferase deletion constructs and EMSA in proliferating vs differentiated RPE cells","pmids":["9856785","9733582"],"confidence":"Medium","gaps":["Identity of the silencer-binding nuclear proteins unknown","Generalizability of basolateral secretion beyond RPE untested"]},{"year":2000,"claim":"Direct protein injection confirmed the dual-mode model, showing full-length FGF5 induces catagen while FGF5S blocks that activity in vivo.","evidence":"Subcutaneous recombinant FGF5/FGF5S injection in depilated mice with histological follicle staging","pmids":["10692103"],"confidence":"High","gaps":["Molecular signaling in follicle not measured in this assay","Receptor identity not directly tested here"]},{"year":2001,"claim":"Receptor-reconstitution experiments identified FGFR1 IIIc and the MEK/MAPK cascade as the route for FGF5-driven proliferation.","evidence":"Stable FGFR-1 IIIc transfection of unresponsive TAKA-1 cells, proliferation and MAPK assays, and PD98059 MEK inhibition; concurrent denervation studies linked FGF5 to Schwann cell biology","pmids":["11876253","11598998"],"confidence":"High","gaps":["Contribution of other FGFRs not excluded","Co-receptor/heparan requirements not addressed"]},{"year":2003,"claim":"Knockout epistasis extended FGF5 function beyond hair to CNS, showing roles in astroglial GFAP expression and blood-brain-barrier integrity, and a receptor-binding peptide validated the FGFR-binding region as the functional determinant.","evidence":"Single/double FGF2-FGF5 mutant mice with GFAP staining, EM of endfeet, albumin extravasation, tight-junction immunoblot and astrocyte rescue; FGF5-derived decapeptide P3 competition and in vivo follicle assays","pmids":["12878680","14502567"],"confidence":"High","gaps":["Direct cellular target of FGF5 in CNS vasculature not pinpointed","Redundancy with FGF2 complicates FGF5-specific attribution"]},{"year":2005,"claim":"Gain-of-function in myocardium revealed a direct hypertrophic and cell-cycle re-entry effect of FGF5 distinct from angiogenesis.","evidence":"Intracoronary AdvFGF-5 in hibernating swine with wall-thickening, myocyte diameter, Ki-67 and phospho-histone H3 measurements","pmids":["15761196"],"confidence":"Medium","gaps":["Receptor/pathway mediating cardiac effect not identified","Single large-animal model"]},{"year":2008,"claim":"Autocrine/paracrine FGF5-FGFR1 IIIc signaling was established as a pro-tumorigenic axis in glioblastoma, generalizing the receptor mechanism to cancer.","evidence":"siRNA knockdown, recombinant FGF5, dominant-negative FGFR1 IIIc, FGFR inhibitors in GBM cells, plus HUVEC angiogenesis assays","pmids":["18362893"],"confidence":"High","gaps":["Driver mutations or amplification status not addressed","Relative autocrine vs paracrine contribution in tumors not quantified"]},{"year":2016,"claim":"Subsequent cancer and vascular studies extended the MAPK/NFAT mitogenic axis to melanoma, osteosarcoma, and endothelial angiogenesis, and tied FGF5 expression to epigenetic regulation and chemoresistance.","evidence":"siRNA in aortic endothelial 3D sprouting; bidirectional manipulation in melanoma with MAPK/NFAT readouts; CRISPR KO/recombinant rescue with MAPK readout and xenograft in osteosarcoma; promoter methylation and cisplatin response in esophageal carcinoma","pmids":["27357248","29152117","31372048","31527639"],"confidence":"Medium","gaps":["Receptor specificity not uniformly tested across these contexts","Whether NFAT activation is FGFR1-dependent unresolved"]},{"year":2014,"claim":"Human genetics and organ culture confirmed FGF5 as a direct catagen inducer in humans and linked its loss to a Mendelian phenotype.","evidence":"Whole-exome sequencing and homozygosity mapping in trichomegaly families plus human hair-follicle organ culture with recombinant FGF5","pmids":["24989505"],"confidence":"High","gaps":["Receptor mediating human follicle regression not directly tested","Genotype-phenotype range across families incompletely defined"]},{"year":2020,"claim":"Livestock knockout and Schwann-cell studies dissected the de-repressed signaling cascades downstream of FGF5 loss and refined its receptor usage and ERK effects in nerve.","evidence":"CRISPR FGF5 KO sheep with FGFR1→AR→Wnt/β-catenin→Shh/Gli2→c-MYC→keratin pathway analysis; injured-nerve profiling, recombinant FGF5 on Schwann cells with ERK, migration, and N-cadherin assays","pmids":["32472005","32848626","26390813","38891117"],"confidence":"Medium","gaps":["Direct versus indirect engagement of each cascade node not resolved","Context-dependent ERK inhibition vs activation by FGF5 unexplained"]},{"year":2022,"claim":"Overexpression studies expanded FGF5 into cytoprotective signaling, implicating CaMKII/NFκB and AKT pathways in protection from pyroptosis and oxidative stress.","evidence":"Adenoviral FGF5 overexpression in cardiomyocyte and endothelial LPS injury models with CaMKII/NFκB and AKT pathway readouts and KN93/MK2206 inhibitors","pmids":["36368152","36244113"],"confidence":"Medium","gaps":["Receptor linking FGF5 to AKT/CaMKII not identified","Physiological relevance beyond overexpression unestablished"]},{"year":2024,"claim":"Dual-gene-edited sheep linked FGF5 loss to skeletal muscle satellite cell regulation through a MEK-ERK-FOSL1-MyoD1 axis.","evidence":"CRISPR MSTN Del73C + FGF5 KO sheep with MEK-ERK-FOSL1, MyoD1, and CaMKII pathway analysis and myotube phenotyping","pmids":["39365728"],"confidence":"Medium","gaps":["FGF5 and MSTN effects confounded by dual editing","FGF5-specific contribution to the muscle phenotype not isolated"]},{"year":null,"claim":"It remains unresolved how FGF5 switches between mitogenic, pro-survival, and ERK-inhibitory outputs across tissues, and which receptor/co-receptor configurations and FGF5S balance dictate context-specific signaling.","evidence":"","pmids":[],"confidence":"Low","gaps":["No structural model of FGF5/FGF5S-FGFR1 IIIc complex","Mechanistic basis for opposite ERK effects across cell types unknown","In vivo stoichiometry of FGF5 vs FGF5S not quantified"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[2,7,12,18]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[2,4,14]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[1,6]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[7,12,15]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[0,13,24]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[12,26,13]}],"complexes":[],"partners":["FGFR1","FGFR2"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P12034","full_name":"Fibroblast growth factor 5","aliases":["Heparin-binding growth factor 5","HBGF-5","Smag-82"],"length_aa":268,"mass_kda":29.6,"function":"Plays an important role in the regulation of cell proliferation and cell differentiation. Required for normal regulation of the hair growth cycle. Functions as an inhibitor of hair elongation by promoting progression from anagen, the growth phase of the hair follicle, into catagen the apoptosis-induced regression phase (By similarity)","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/P12034/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/FGF5","classification":"Not Classified","n_dependent_lines":3,"n_total_lines":1208,"dependency_fraction":0.0024834437086092716},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/FGF5","total_profiled":1310},"omim":[{"mim_id":"610575","title":"R-SPONDIN 2; RSPO2","url":"https://www.omim.org/entry/610575"},{"mim_id":"608245","title":"KERATIN 71, TYPE II; KRT71","url":"https://www.omim.org/entry/608245"},{"mim_id":"604479","title":"SIRTUIN 1; SIRT1","url":"https://www.omim.org/entry/604479"},{"mim_id":"601513","title":"FIBROBLAST GROWTH FACTOR 12; FGF12","url":"https://www.omim.org/entry/601513"},{"mim_id":"190330","title":"TRICHOMEGALY; TCMGLY","url":"https://www.omim.org/entry/190330"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"brain","ntpm":2.8},{"tissue":"gallbladder","ntpm":2.6},{"tissue":"intestine","ntpm":1.1}],"url":"https://www.proteinatlas.org/search/FGF5"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"P12034","domains":[{"cath_id":"2.80.10.50","chopping":"84-218","consensus_level":"high","plddt":96.0739,"start":84,"end":218}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P12034","model_url":"https://alphafold.ebi.ac.uk/files/AF-P12034-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P12034-F1-predicted_aligned_error_v6.png","plddt_mean":75.69},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=FGF5","jax_strain_url":"https://www.jax.org/strain/search?query=FGF5"},"sequence":{"accession":"P12034","fasta_url":"https://rest.uniprot.org/uniprotkb/P12034.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P12034/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P12034"}},"corpus_meta":[{"pmid":"7923352","id":"PMC_7923352","title":"FGF5 as a regulator of the hair growth cycle: evidence from targeted and spontaneous mutations.","date":"1994","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/7923352","citation_count":483,"is_preprint":false},{"pmid":"3211147","id":"PMC_3211147","title":"The human FGF-5 oncogene encodes a novel protein related to fibroblast growth factors.","date":"1988","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/3211147","citation_count":427,"is_preprint":false},{"pmid":"1794311","id":"PMC_1794311","title":"mRNA localization studies suggest that murine FGF-5 plays a role in gastrulation.","date":"1991","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/1794311","citation_count":179,"is_preprint":false},{"pmid":"25998163","id":"PMC_25998163","title":"MicroRNA-188-5p suppresses tumor cell proliferation and metastasis by directly targeting FGF5 in hepatocellular carcinoma.","date":"2015","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/25998163","citation_count":161,"is_preprint":false},{"pmid":"24989505","id":"PMC_24989505","title":"FGF5 is a crucial regulator of hair length in humans.","date":"2014","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/24989505","citation_count":137,"is_preprint":false},{"pmid":"26354037","id":"PMC_26354037","title":"Generation of gene-modified goats targeting MSTN and FGF5 via zygote injection of CRISPR/Cas9 system.","date":"2015","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/26354037","citation_count":134,"is_preprint":false},{"pmid":"12878680","id":"PMC_12878680","title":"Functions of fibroblast growth factor (FGF)-2 and FGF-5 in astroglial differentiation and blood-brain barrier permeability: evidence from mouse mutants.","date":"2003","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/12878680","citation_count":126,"is_preprint":false},{"pmid":"9856785","id":"PMC_9856785","title":"Use of the ARPE-19 cell line as a model of RPE polarity: basolateral secretion of FGF5.","date":"1998","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/9856785","citation_count":111,"is_preprint":false},{"pmid":"18362893","id":"PMC_18362893","title":"FGF5 as an oncogenic factor in human glioblastoma multiforme: autocrine and paracrine activities.","date":"2008","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/18362893","citation_count":86,"is_preprint":false},{"pmid":"15761196","id":"PMC_15761196","title":"Adenoviral gene transfer of FGF-5 to hibernating myocardium improves function and stimulates myocytes to hypertrophy and reenter the cell cycle.","date":"2005","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/15761196","citation_count":80,"is_preprint":false},{"pmid":"17433015","id":"PMC_17433015","title":"Mutations within the FGF5 gene are associated with hair length in cats.","date":"2007","source":"Animal genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17433015","citation_count":79,"is_preprint":false},{"pmid":"10692103","id":"PMC_10692103","title":"Dual-mode regulation of hair growth cycle by two Fgf-5 gene products.","date":"2000","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/10692103","citation_count":76,"is_preprint":false},{"pmid":"1478282","id":"PMC_1478282","title":"Coexpression of FGF-5 and bFGF by the retinal pigment epithelium in vitro.","date":"1992","source":"Experimental eye research","url":"https://pubmed.ncbi.nlm.nih.gov/1478282","citation_count":76,"is_preprint":false},{"pmid":"16879338","id":"PMC_16879338","title":"The long and the short of it: evidence that FGF5 is a major determinant of canine 'hair'-itability.","date":"2006","source":"Animal genetics","url":"https://pubmed.ncbi.nlm.nih.gov/16879338","citation_count":69,"is_preprint":false},{"pmid":"20852445","id":"PMC_20852445","title":"Common variants in or near FGF5, CYP17A1 and MTHFR genes are associated with blood pressure and hypertension in Chinese Hans.","date":"2011","source":"Journal of hypertension","url":"https://pubmed.ncbi.nlm.nih.gov/20852445","citation_count":68,"is_preprint":false},{"pmid":"11319911","id":"PMC_11319911","title":"Two animal models of retinal degeneration are rescued by recombinant adeno-associated virus-mediated production of FGF-5 and FGF-18.","date":"2001","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/11319911","citation_count":67,"is_preprint":false},{"pmid":"27755602","id":"PMC_27755602","title":"Disruption of FGF5 in Cashmere Goats Using CRISPR/Cas9 Results in More Secondary Hair Follicles and Longer Fibers.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/27755602","citation_count":66,"is_preprint":false},{"pmid":"9856803","id":"PMC_9856803","title":"Localization of rat FGF-5 protein in skin macrophage-like cells and FGF-5S protein in hair follicle: possible involvement of two Fgf-5 gene products in hair growth cycle regulation.","date":"1998","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/9856803","citation_count":56,"is_preprint":false},{"pmid":"27357248","id":"PMC_27357248","title":"Intrinsic FGF2 and FGF5 promotes angiogenesis of human aortic endothelial cells in 3D microfluidic angiogenesis system.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27357248","citation_count":54,"is_preprint":false},{"pmid":"23384345","id":"PMC_23384345","title":"Allelic heterogeneity of FGF5 mutations causes the long-hair phenotype in dogs.","date":"2013","source":"Animal genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23384345","citation_count":50,"is_preprint":false},{"pmid":"28631368","id":"PMC_28631368","title":"CRISPR/Cas9-mediated loss of FGF5 function increases wool staple length in sheep.","date":"2017","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/28631368","citation_count":46,"is_preprint":false},{"pmid":"32472005","id":"PMC_32472005","title":"Crosstalk between androgen and Wnt/β-catenin leads to changes of wool density in FGF5-knockout sheep.","date":"2020","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/32472005","citation_count":45,"is_preprint":false},{"pmid":"26390813","id":"PMC_26390813","title":"Fibroblast growth factor 5-short (FGF5s) inhibits the activity of FGF5 in primary and secondary hair follicle dermal papilla cells of cashmere goats.","date":"2015","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/26390813","citation_count":42,"is_preprint":false},{"pmid":"25927731","id":"PMC_25927731","title":"Two recessive mutations in FGF5 are associated with the long-hair phenotype in donkeys.","date":"2014","source":"Genetics, selection, evolution : GSE","url":"https://pubmed.ncbi.nlm.nih.gov/25927731","citation_count":39,"is_preprint":false},{"pmid":"31272285","id":"PMC_31272285","title":"Downregulation of miR-145-5p elevates retinal ganglion cell survival to delay diabetic retinopathy progress by targeting FGF5.","date":"2019","source":"Bioscience, biotechnology, and biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31272285","citation_count":34,"is_preprint":false},{"pmid":"8045713","id":"PMC_8045713","title":"Distribution of FGF-5 in the rhesus macaque retina.","date":"1994","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/8045713","citation_count":34,"is_preprint":false},{"pmid":"31372048","id":"PMC_31372048","title":"FGF5 promotes osteosarcoma cells proliferation via activating MAPK signaling pathway.","date":"2019","source":"Cancer management and research","url":"https://pubmed.ncbi.nlm.nih.gov/31372048","citation_count":32,"is_preprint":false},{"pmid":"31276295","id":"PMC_31276295","title":"Base pair editing in goat: nonsense codon introgression into FGF5 results in longer hair.","date":"2019","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/31276295","citation_count":32,"is_preprint":false},{"pmid":"29743851","id":"PMC_29743851","title":"MicroRNA-567 inhibits cell proliferation, migration and invasion by targeting FGF5 in osteosarcoma.","date":"2018","source":"EXCLI journal","url":"https://pubmed.ncbi.nlm.nih.gov/29743851","citation_count":31,"is_preprint":false},{"pmid":"11066093","id":"PMC_11066093","title":"FGF5 stimulates expansion of connective tissue fibroblasts and inhibits skeletal muscle development in the limb.","date":"2000","source":"Developmental dynamics : an official publication of the American Association of Anatomists","url":"https://pubmed.ncbi.nlm.nih.gov/11066093","citation_count":31,"is_preprint":false},{"pmid":"9786939","id":"PMC_9786939","title":"An alternatively spliced fibroblast growth factor (FGF)-5 mRNA is abundant in brain and translates into a partial agonist/antagonist for FGF-5 neurotrophic activity.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9786939","citation_count":31,"is_preprint":false},{"pmid":"34305588","id":"PMC_34305588","title":"Suppression of FGF5 and FGF18 Expression by Cholesterol-Modified siRNAs Promotes Hair Growth in Mice.","date":"2021","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/34305588","citation_count":30,"is_preprint":false},{"pmid":"29152117","id":"PMC_29152117","title":"FGF5 is expressed in melanoma and enhances malignancy in vitro and in vivo.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29152117","citation_count":28,"is_preprint":false},{"pmid":"33416186","id":"PMC_33416186","title":"Hsa_circ_0016760 exacerbates the malignant development of non‑small cell lung cancer by sponging miR‑145‑5p/FGF5.","date":"2020","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/33416186","citation_count":28,"is_preprint":false},{"pmid":"28727005","id":"PMC_28727005","title":"RAPID COMMUNICATION: Generation of FGF5 knockout sheep via the CRISPR/Cas9 system.","date":"2017","source":"Journal of animal science","url":"https://pubmed.ncbi.nlm.nih.gov/28727005","citation_count":26,"is_preprint":false},{"pmid":"8611621","id":"PMC_8611621","title":"The rat FGF-5 mRNA variant generated by alternative splicing encodes a novel truncated form of FGF-5.","date":"1996","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/8611621","citation_count":26,"is_preprint":false},{"pmid":"14502567","id":"PMC_14502567","title":"Decapeptide with fibroblast growth factor (FGF)-5 partial sequence inhibits hair growth suppressing activity of FGF-5.","date":"2003","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/14502567","citation_count":25,"is_preprint":false},{"pmid":"28280377","id":"PMC_28280377","title":"Promotion of anagen, increased hair density and reduction of hair fall in a clinical setting following identification of FGF5-inhibiting compounds via a novel 2-stage process.","date":"2017","source":"Clinical, cosmetic and investigational dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/28280377","citation_count":25,"is_preprint":false},{"pmid":"32848626","id":"PMC_32848626","title":"FGF5 Regulates Schwann Cell Migration and Adhesion.","date":"2020","source":"Frontiers in cellular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/32848626","citation_count":24,"is_preprint":false},{"pmid":"23394579","id":"PMC_23394579","title":"Characterization of hairless (Hr) and FGF5 genes provides insights into the molecular basis of hair loss in cetaceans.","date":"2013","source":"BMC evolutionary biology","url":"https://pubmed.ncbi.nlm.nih.gov/23394579","citation_count":24,"is_preprint":false},{"pmid":"2317376","id":"PMC_2317376","title":"Chromosome assignment by polymerase chain reaction techniques: assignment of the oncogene FGF-5 to human chromosome 4.","date":"1990","source":"BioTechniques","url":"https://pubmed.ncbi.nlm.nih.gov/2317376","citation_count":23,"is_preprint":false},{"pmid":"33536494","id":"PMC_33536494","title":"Specific inhibition of FGF5-induced cell proliferation by RNA aptamers.","date":"2021","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/33536494","citation_count":21,"is_preprint":false},{"pmid":"9134330","id":"PMC_9134330","title":"Expression of FGF5 in choroidal neovascular membranes associated with ARMD.","date":"1997","source":"Current eye research","url":"https://pubmed.ncbi.nlm.nih.gov/9134330","citation_count":20,"is_preprint":false},{"pmid":"29804124","id":"PMC_29804124","title":"Expression of Fibroblast Growth Factor 5 (FGF5) and Its Influence on Survival of Breast Cancer Patients.","date":"2018","source":"Medical science monitor : international medical journal of experimental and clinical research","url":"https://pubmed.ncbi.nlm.nih.gov/29804124","citation_count":18,"is_preprint":false},{"pmid":"34659356","id":"PMC_34659356","title":"Five SNPs Within the FGF5 Gene Significantly Affect Both Wool Traits and Growth Performance in Fine-Wool Sheep (Ovis aries).","date":"2021","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/34659356","citation_count":18,"is_preprint":false},{"pmid":"21512271","id":"PMC_21512271","title":"Retrotransposon-mediated Fgf5(go-Utr) mutant mice with long pelage hair.","date":"2011","source":"Experimental animals","url":"https://pubmed.ncbi.nlm.nih.gov/21512271","citation_count":18,"is_preprint":false},{"pmid":"39365728","id":"PMC_39365728","title":"A MSTNDel73C mutation with FGF5 knockout sheep by CRISPR/Cas9 promotes skeletal muscle myofiber hyperplasia.","date":"2024","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/39365728","citation_count":17,"is_preprint":false},{"pmid":"36368152","id":"PMC_36368152","title":"FGF5 protects heart from sepsis injury by attenuating cardiomyocyte pyroptosis through inhibiting CaMKII/NFκB signaling.","date":"2022","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/36368152","citation_count":17,"is_preprint":false},{"pmid":"27409080","id":"PMC_27409080","title":"Visualization of the Epiblast and Visceral Endodermal Cells Using Fgf5-P2A-Venus BAC Transgenic Mice and Epiblast Stem Cells.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/27409080","citation_count":17,"is_preprint":false},{"pmid":"11876253","id":"PMC_11876253","title":"Expression of the IIIc variant of FGF receptor-1 confers mitogenic responsiveness to heparin and FGF-5 in TAKA-1 pancreatic ductal cells.","date":"2001","source":"International journal of pancreatology : official journal of the International Association of Pancreatology","url":"https://pubmed.ncbi.nlm.nih.gov/11876253","citation_count":17,"is_preprint":false},{"pmid":"31527639","id":"PMC_31527639","title":"FGF5 methylation is a sensitivity marker of esophageal squamous cell carcinoma to definitive chemoradiotherapy.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/31527639","citation_count":16,"is_preprint":false},{"pmid":"26481120","id":"PMC_26481120","title":"A 1-bp deletion in Fgf5 causes male-dominant long hair in the Syrian hamster.","date":"2015","source":"Mammalian genome : official journal of the International Mammalian Genome Society","url":"https://pubmed.ncbi.nlm.nih.gov/26481120","citation_count":16,"is_preprint":false},{"pmid":"9221924","id":"PMC_9221924","title":"Transient expression of FGF-5 mRNA in the rat cerebellar cortex during post-natal development.","date":"1997","source":"Brain research. Molecular brain research","url":"https://pubmed.ncbi.nlm.nih.gov/9221924","citation_count":16,"is_preprint":false},{"pmid":"29024003","id":"PMC_29024003","title":"Molecular characterization of the llama FGF5 gene and identification of putative loss of function mutations.","date":"2017","source":"Animal genetics","url":"https://pubmed.ncbi.nlm.nih.gov/29024003","citation_count":14,"is_preprint":false},{"pmid":"35380267","id":"PMC_35380267","title":"Genetic susceptibility analysis of FGF5 polymorphism to preeclampsia in Chinese Han population.","date":"2022","source":"Molecular genetics and genomics : MGG","url":"https://pubmed.ncbi.nlm.nih.gov/35380267","citation_count":14,"is_preprint":false},{"pmid":"33660806","id":"PMC_33660806","title":"SP1-induced lncRNA TUG1 regulates proliferation and apoptosis in islet cells of type 2 diabetes mellitus via the miR-188-3p/FGF5 axis.","date":"2021","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33660806","citation_count":14,"is_preprint":false},{"pmid":"11598998","id":"PMC_11598998","title":"Axon-Schwann cell interactions regulate the expression of fibroblast growth factor-5 (FGF-5).","date":"2001","source":"Journal of neuroscience research","url":"https://pubmed.ncbi.nlm.nih.gov/11598998","citation_count":14,"is_preprint":false},{"pmid":"25445274","id":"PMC_25445274","title":"Molecular cloning, characterization, and expression of sheep FGF5 gene.","date":"2014","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/25445274","citation_count":13,"is_preprint":false},{"pmid":"22634565","id":"PMC_22634565","title":"Cloning and expression analysis of Fgf5, 6 and 7 during early chick development.","date":"2012","source":"Gene expression patterns : GEP","url":"https://pubmed.ncbi.nlm.nih.gov/22634565","citation_count":11,"is_preprint":false},{"pmid":"30757935","id":"PMC_30757935","title":"Eclipta prostrata promotes the induction of anagen, sustains the anagen phase through regulation of FGF-7 and FGF-5.","date":"2019","source":"Pharmaceutical biology","url":"https://pubmed.ncbi.nlm.nih.gov/30757935","citation_count":10,"is_preprint":false},{"pmid":"34585489","id":"PMC_34585489","title":"FGF5 and EPAS1 gene polymorphisms are associated with high-altitude adaptation in Nepalese goat breeds.","date":"2021","source":"Animal science journal = Nihon chikusan Gakkaiho","url":"https://pubmed.ncbi.nlm.nih.gov/34585489","citation_count":9,"is_preprint":false},{"pmid":"35880306","id":"PMC_35880306","title":"The Lnc-RNA APPAT Suppresses Human Aortic Smooth Muscle Cell Proliferation and Migration by Interacting With MiR-647 and FGF5 in Atherosclerosis.","date":"2022","source":"Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists","url":"https://pubmed.ncbi.nlm.nih.gov/35880306","citation_count":8,"is_preprint":false},{"pmid":"29307854","id":"PMC_29307854","title":"Evidence of post-transcriptional readthrough regulation in FGF5 gene of alpaca.","date":"2018","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/29307854","citation_count":8,"is_preprint":false},{"pmid":"35341378","id":"PMC_35341378","title":"Circ_0041732 regulates tumor properties of triple-negative breast cancer cells by the miR-149-5p/FGF5 pathway.","date":"2022","source":"The International journal of biological markers","url":"https://pubmed.ncbi.nlm.nih.gov/35341378","citation_count":7,"is_preprint":false},{"pmid":"36808266","id":"PMC_36808266","title":"Circ_0001715 Functions as a miR-1249-3p Sponge to Accelerate the Progression of Non-small Cell Lung Cancer via Upregulating the Level of FGF5.","date":"2023","source":"Biochemical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/36808266","citation_count":7,"is_preprint":false},{"pmid":"18779133","id":"PMC_18779133","title":"[Correlation analysis between single nucleotide polymorphism of FGF5 gene and wool yield in rabbits].","date":"2008","source":"Yi chuan = Hereditas","url":"https://pubmed.ncbi.nlm.nih.gov/18779133","citation_count":7,"is_preprint":false},{"pmid":"12754391","id":"PMC_12754391","title":"Expression of the IIIc Variant of FGF Receptor-1 Confers Mitogenic Responsiveness to Heparin and FGF-5 in TAKA-1 Pancreatic Ductal Cells.","date":"2001","source":"International journal of gastrointestinal cancer","url":"https://pubmed.ncbi.nlm.nih.gov/12754391","citation_count":7,"is_preprint":false},{"pmid":"37065235","id":"PMC_37065235","title":"Reproduction and viscera organ characteristics of MSTN and FGF5 dual-gene knockout sheep.","date":"2023","source":"Frontiers in veterinary science","url":"https://pubmed.ncbi.nlm.nih.gov/37065235","citation_count":6,"is_preprint":false},{"pmid":"38891117","id":"PMC_38891117","title":"Increasing GSH-Px Activity and Activating Wnt Pathway Promote Fine Wool Growth in FGF5-Edited Sheep.","date":"2024","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/38891117","citation_count":6,"is_preprint":false},{"pmid":"34432312","id":"PMC_34432312","title":"FGF5 missense mutation is associated with dromedary hair length variation.","date":"2021","source":"Animal genetics","url":"https://pubmed.ncbi.nlm.nih.gov/34432312","citation_count":6,"is_preprint":false},{"pmid":"26535691","id":"PMC_26535691","title":"Alpaca fiber growth is mediated by microRNA let-7b via down-regulation of target gene FGF5.","date":"2015","source":"Genetics and molecular research : GMR","url":"https://pubmed.ncbi.nlm.nih.gov/26535691","citation_count":6,"is_preprint":false},{"pmid":"38148937","id":"PMC_38148937","title":"Potential roles of FGF5 as a candidate therapeutic target in prostate cancer.","date":"2023","source":"American journal of clinical and experimental urology","url":"https://pubmed.ncbi.nlm.nih.gov/38148937","citation_count":5,"is_preprint":false},{"pmid":"36244113","id":"PMC_36244113","title":"FGF5 alleviated acute lung injury via AKT signal pathway in endothelial cells.","date":"2022","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/36244113","citation_count":5,"is_preprint":false},{"pmid":"26400346","id":"PMC_26400346","title":"Cloning, molecular characterization, and expression pattern of FGF5 in Cashmere goat (Capra hircus).","date":"2015","source":"Genetics and molecular research : GMR","url":"https://pubmed.ncbi.nlm.nih.gov/26400346","citation_count":5,"is_preprint":false},{"pmid":"35207492","id":"PMC_35207492","title":"A 90-Day Safety Study of Meat from MSTN and FGF5 Double-Knockout Sheep in Wistar Rats.","date":"2022","source":"Life (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/35207492","citation_count":5,"is_preprint":false},{"pmid":"19273426","id":"PMC_19273426","title":"[Effects of FGF5 gene on fibre traits on Inner Mongolian cashmere goats].","date":"2009","source":"Yi chuan = Hereditas","url":"https://pubmed.ncbi.nlm.nih.gov/19273426","citation_count":5,"is_preprint":false},{"pmid":"9733582","id":"PMC_9733582","title":"Differentiation of retinal pigment epithelial cells in vitro uncovers silencer activity in the FGF-5 gene promoter.","date":"1998","source":"Experimental eye research","url":"https://pubmed.ncbi.nlm.nih.gov/9733582","citation_count":5,"is_preprint":false},{"pmid":"38926663","id":"PMC_38926663","title":"Metabolic differences in MSTN and FGF5 dual-gene edited sheep muscle cells during myogenesis.","date":"2024","source":"BMC genomics","url":"https://pubmed.ncbi.nlm.nih.gov/38926663","citation_count":4,"is_preprint":false},{"pmid":"38674344","id":"PMC_38674344","title":"Regulation of Hair Follicle Growth and Development by Different Alternative Spliceosomes of FGF5 in Rabbits.","date":"2024","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/38674344","citation_count":4,"is_preprint":false},{"pmid":"36917699","id":"PMC_36917699","title":"Global Long Noncoding RNA Expression Profiling of MSTN and FGF5 Double-Knockout Sheep Reveals the Key Gatekeepers of Skeletal Muscle Development.","date":"2023","source":"DNA and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/36917699","citation_count":4,"is_preprint":false},{"pmid":"40001587","id":"PMC_40001587","title":"Multi-Omics Characterization of Genome-Wide Abnormal DNA Methylation Reveals FGF5 as a Diagnosis of Nasopharyngeal Carcinoma Recurrence After Radiotherapy.","date":"2025","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/40001587","citation_count":4,"is_preprint":false},{"pmid":"36233155","id":"PMC_36233155","title":"Gender-Difference in Hair Length as Revealed by Crispr-Based Production of Long-Haired Mice with Dysfunctional FGF5 Mutations.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36233155","citation_count":4,"is_preprint":false},{"pmid":"37957094","id":"PMC_37957094","title":"FGF5.","date":"2023","source":"Differentiation; research in biological diversity","url":"https://pubmed.ncbi.nlm.nih.gov/37957094","citation_count":3,"is_preprint":false},{"pmid":"36905676","id":"PMC_36905676","title":"Fibroblast growth factor 5 (FGF5) and its missense mutant FGF5-H174 underlying trichomegaly: a molecular dynamics simulation investigation.","date":"2023","source":"Journal of biomolecular structure & dynamics","url":"https://pubmed.ncbi.nlm.nih.gov/36905676","citation_count":3,"is_preprint":false},{"pmid":"36916144","id":"PMC_36916144","title":"A rare FGF5 candidate variant (rs112475347) for predisposition to nonsquamous, nonsmall-cell lung cancer.","date":"2023","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/36916144","citation_count":3,"is_preprint":false},{"pmid":"35052442","id":"PMC_35052442","title":"Tracing the Origin of the RSPO2 Long-Hair Allele and Epistatic Interaction between FGF5 and RSPO2 in Sapsaree Dog.","date":"2022","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/35052442","citation_count":3,"is_preprint":false},{"pmid":"11715949","id":"PMC_11715949","title":"Technology evaluation: gene therapy (FGF-5), Vical.","date":"1999","source":"Current opinion in molecular therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/11715949","citation_count":3,"is_preprint":false},{"pmid":"35119014","id":"PMC_35119014","title":"The rs1458038 variant near FGF5 is associated with poor response to calcium channel blockers among Filipinos.","date":"2022","source":"Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35119014","citation_count":3,"is_preprint":false},{"pmid":"22567929","id":"PMC_22567929","title":"[Interaction of mutant genes Fgf5(go-Y), we, and wal changes the duration of hair growth cycles in mice].","date":"2012","source":"Ontogenez","url":"https://pubmed.ncbi.nlm.nih.gov/22567929","citation_count":3,"is_preprint":false},{"pmid":"21951799","id":"PMC_21951799","title":"[Cloning, expression analysis and RNA interference of FGF5 gene in sheep].","date":"2011","source":"Yi chuan = Hereditas","url":"https://pubmed.ncbi.nlm.nih.gov/21951799","citation_count":1,"is_preprint":false},{"pmid":"40869975","id":"PMC_40869975","title":"Genetic Variant of the Canine FGF5 Gene for the Hair Length Trait in the Akita: Utility for Hair Coat Variations and Welfare in Conservation Breeding.","date":"2025","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/40869975","citation_count":0,"is_preprint":false},{"pmid":"40913740","id":"PMC_40913740","title":"FGF5 alleviates ferroptosis in renal tubular epithelial cells by inducing mitophagy under in vitro ischemia-reperfusion-like injury.","date":"2025","source":"Journal of molecular histology","url":"https://pubmed.ncbi.nlm.nih.gov/40913740","citation_count":0,"is_preprint":false},{"pmid":"41773981","id":"PMC_41773981","title":"FGF5 Allelic Heterogeneity in Long-Haired Belgian Shepherd Dogs.","date":"2026","source":"Animal genetics","url":"https://pubmed.ncbi.nlm.nih.gov/41773981","citation_count":0,"is_preprint":false},{"pmid":"41828909","id":"PMC_41828909","title":"Discovery of Four New FGF5 Variants Causing Long Hair in the Dog.","date":"2026","source":"Animals : an open access journal from MDPI","url":"https://pubmed.ncbi.nlm.nih.gov/41828909","citation_count":0,"is_preprint":false},{"pmid":"42239286","id":"PMC_42239286","title":"Integrative Genomic Analyses Identify COL21A1 and ENPEP-FGF5 Regulatory Pathways for Blood Pressure Variation in East Asians.","date":"2026","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/42239286","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":47510,"output_tokens":8362,"usd":0.13398,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":17827,"output_tokens":4945,"usd":0.10638,"stage2_stop_reason":"end_turn"},"total_usd":0.24036,"stage1_batch_id":"msgbatch_01AsR7g8dGTEiEw9U83bJeWn","stage2_batch_id":"msgbatch_01YV5ZyxtFNUZEjxRcpd9jzb","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1994,\n      \"finding\": \"FGF5 functions as an inhibitor of hair elongation and regulator of the anagen-to-catagen transition in the hair growth cycle. Mice homozygous for a targeted null allele (fgf5neo) or the spontaneous angora (go) mutation — shown to be a deletion in Fgf5 exon 1 — display abnormally long hair. FGF5 mRNA is expressed in the outer root sheath of hair follicles specifically during anagen VI.\",\n      \"method\": \"Gene targeting in ES cells (null allele), complementation test with spontaneous mutant (go), RNA in situ hybridization in wild-type hair follicles\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — genetic null + spontaneous mutant complementation + spatial expression, replicated by multiple independent mutant alleles\",\n      \"pmids\": [\"7923352\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1988,\n      \"finding\": \"FGF5 encodes a secreted protein with ~40–50% amino acid homology to acidic and basic FGFs across two conserved regions (122 of 267 residues), sharing the three-exon gene structure typical of the FGF family. FGF5 transforming activity was activated by juxtaposition of a retroviral transcriptional enhancer upstream of the native promoter during transfection.\",\n      \"method\": \"cDNA cloning, sequence homology analysis, NIH 3T3 transformation assay, structural genomic analysis\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — direct sequencing and in vitro transformation assay establishing protein identity and activating rearrangement mechanism\",\n      \"pmids\": [\"3211147\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"An alternatively spliced FGF5 mRNA (FGF5S), lacking exon 2, encodes a 121–123 amino acid truncated protein. FGF5S acts as a partial agonist/antagonist of FGF5: it binds FGFR1, partially inhibits FGF5-induced FGFR1 tyrosine phosphorylation and downstream signaling, and at high concentrations partially antagonizes FGF5-induced PC12 cell differentiation, while exerting very weak neurotrophic activity alone.\",\n      \"method\": \"cDNA cloning, RT-PCR, genomic analysis, PC12 cell differentiation assays, FGFR1 tyrosine phosphorylation assay, competitive binding to FGFR1\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — receptor binding, phosphorylation assay, and functional differentiation assay in single study with multiple orthogonal methods\",\n      \"pmids\": [\"9786939\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Rat FGF5 alternative splicing generates a short-form mRNA (FGF5S) by exclusion of exon 2, encoding a 121-amino acid truncated protein whose N-terminal 117 residues are identical to those of full-length FGF5. Both FGF5 and FGF5S mRNAs are expressed in embryo and adult brain.\",\n      \"method\": \"cDNA cloning, RT-PCR, genomic exon mapping\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cDNA cloning with genomic structure confirmation, single lab, two methods (RT-PCR + genomic sequencing)\",\n      \"pmids\": [\"8611621\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"FGF5 (full-length) induces catagen and inhibits hair growth during anagen when injected subcutaneously in depilated mice. FGF5S alone has no effect on hair growth but significantly inhibits the catagen-promoting activity of FGF5 when co-injected, indicating dual-mode regulation of the hair cycle by the two Fgf5 gene products.\",\n      \"method\": \"Subcutaneous injection of recombinant FGF5 and FGF5S proteins into depilated mice; histological analysis of hair follicle stage\",\n      \"journal\": \"The Journal of investigative dermatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo protein injection with defined phenotypic readout, consistent with mechanism proposed by genetic studies\",\n      \"pmids\": [\"10692103\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"In rat skin, FGF5 protein localizes to macrophage-like cells in the dermis (density correlated with hair cycle phase), while FGF5S protein localizes specifically to hair follicles (high in early anagen VI, decreasing in catagen), suggesting distinct compartmentalization of the two Fgf5 gene products during the hair cycle.\",\n      \"method\": \"Immunohistochemistry with isoform-specific monoclonal antibodies (E723 for FGF5 long-form; B2B6 for both forms) on rat skin sections at defined hair cycle stages\",\n      \"journal\": \"The Journal of investigative dermatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — isoform-specific antibody immunohistochemistry across hair cycle stages, single lab, two antibody probes\",\n      \"pmids\": [\"9856803\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"FGF5 is secreted vectorially from the basolateral surface of polarized RPE (ARPE-19) cells: >90% of total secreted FGF5 accumulates in basolateral media over 6 hours, as determined by immunoblot of conditioned media from adenovirus-transduced polarized monolayers.\",\n      \"method\": \"Adenovirus-mediated FGF5 gene transfer into polarized ARPE-19 monolayers; domain-selective collection and immunoblot analysis of conditioned apical vs. basolateral media\",\n      \"journal\": \"Investigative ophthalmology & visual science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct secretion polarity assay with quantitative immunoblot, single lab, single method\",\n      \"pmids\": [\"9856785\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"FGF5-induced mitogenesis in pancreatic ductal cells is mediated specifically through the IIIc splice variant of FGFR1 via the MAPK pathway: TAKA-1 cells that do not express FGFR1 are unresponsive to FGF5, but TAKA-1 clones stably expressing FGFR-1 IIIc show growth stimulation and enhanced MAPK activity in response to FGF5; the MEK inhibitor PD98059 blocks this effect.\",\n      \"method\": \"Stable transfection of FGFR-1 IIIc cDNA into TAKA-1 cells; cell proliferation assay; MAPK activity assay; MEK inhibitor (PD98059) treatment\",\n      \"journal\": \"International journal of pancreatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — gain-of-function receptor expression, proliferation assay, pathway inhibitor, multiple orthogonal methods in single study\",\n      \"pmids\": [\"11876253\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Denervated Schwann cells upregulate FGF5 mRNA and protein following axotomy; axon-Schwann cell contact suppresses FGF5 expression in regenerating sciatic nerve; forskolin also diminishes FGF5 mRNA in cultured Schwann cells, indicating that axon-Schwann cell interactions negatively regulate FGF5 expression.\",\n      \"method\": \"cDNA array screening, Northern blotting, in situ hybridization, Western blotting of axotomized rat sciatic nerve; cultured Schwann cells treated with forskolin\",\n      \"journal\": \"Journal of neuroscience research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — multiple validation methods (Northern, ISH, Western) in single lab for expression regulation, functional context established\",\n      \"pmids\": [\"11598998\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"FGF-5 (together with FGF-2) regulates astroglial differentiation in vivo: FGF-5-/- mice show region-specific reduction in GFAP in midbrain tegmentum astrocytes. In FGF-2-/-/FGF-5-/- double mutant mice, GFAP is reduced in cortex, striatum, and midbrain, intermediate filaments in perivascular endfeet are decreased, and blood-brain barrier permeability is enhanced (albumin extravasation; reduced Occludin and ZO-1 levels).\",\n      \"method\": \"Single and double mutant mouse analysis; GFAP and S100 immunostaining; electron microscopy of perivascular endfeet; albumin extravasation assay; tight junction protein (Occludin, ZO-1) immunoblot; cortical astrocyte cultures with exogenous FGF rescue\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis with single and double knockouts, multiple orthogonal methods, functional rescue experiment\",\n      \"pmids\": [\"12878680\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"A decapeptide (P3: 95-VGIGFHLQIY-104) corresponding to a receptor-binding region of FGF5 suppresses FGF5-induced proliferation of fibroblasts and FGFR-1c-expressing Ba/F3 cells in vitro, partially inhibits FGF5 binding to FGFR-1(IIIc)/Fc chimera, and reduces FGF5-induced inhibition of hair follicle growth and cell proliferation in vivo.\",\n      \"method\": \"Peptide synthesis; cell proliferation assay (BALB/3T3, NIH/3T3, FGFR-1c Ba/F3); competitive receptor-binding assay (FGFR-1(IIIc)/Fc chimera); in vivo depilated mouse model; anti-Ki67 staining of hair follicles\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — receptor binding competition plus cellular and in vivo functional assays, single lab\",\n      \"pmids\": [\"14502567\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Adenoviral overexpression of FGF-5 in hibernating swine myocardium improves wall thickening, induces profound myocyte cellular hypertrophy, and causes a 7-fold increase in Ki-67-positive myocytes and increased phospho-histone H3-positive myocytes, demonstrating that FGF-5 directly stimulates hypertrophy and myocyte cell cycle re-entry rather than angiogenesis in cardiac muscle.\",\n      \"method\": \"Intracoronary injection of replication-deficient AdvFGF-5 in swine; echocardiographic wall-thickening measurement; histological myocyte diameter measurement; Ki-67 and phospho-histone H3 immunostaining; flow measurement\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo gain-of-function with multiple histological readouts, single lab, large animal model\",\n      \"pmids\": [\"15761196\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"FGF5 promotes GBM cell proliferation and survival via autocrine/paracrine signaling through FGFR1 IIIc: siRNA-mediated FGF5 knockdown reduces proliferation and increases apoptosis; recombinant FGF5 promotes proliferation and prevents apoptosis; dominant-negative FGFR1 IIIc or pharmacological FGFR inhibitors block these effects. FGF5 also stimulates HUVEC proliferation, migration, and tube formation (paracrine angiogenic effect).\",\n      \"method\": \"siRNA knockdown; recombinant FGF5 treatment; dominant-negative FGFR1 IIIc expression; pharmacological FGFR inhibitors; cell proliferation, apoptosis, migration assays; HUVEC tube formation assay\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (siRNA, dominant-negative, inhibitor, recombinant protein) in single study establishing autocrine FGFR1 IIIc signaling\",\n      \"pmids\": [\"18362893\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Loss-of-function mutations in human FGF5 cause trichomegaly (extreme eyelash growth) inherited in an autosomal recessive pattern. Hair follicle organ culture experiments show that exogenous FGF5 protein induces regression of the human hair follicle, confirming FGF5 as a direct inducer of follicle catagen in humans.\",\n      \"method\": \"Whole exome sequencing and homozygosity mapping in trichomegaly families; hair follicle organ culture with recombinant FGF5; anagen:telogen ratio measurement\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — human genetics plus direct organ culture functional assay, replication across multiple families\",\n      \"pmids\": [\"24989505\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"In cashmere goat dermal papilla cells, FGF5 overexpression upregulates IGF-1, versican, and noggin mRNA (anagen maintenance factors) and downregulates BMP4 (catagen signal); FGF5S overexpression partially reverses these effects, demonstrating FGF5S acts as an inhibitor of FGF5 function in dermal papilla cells.\",\n      \"method\": \"Adenovirus-mediated overexpression of FGF5 and FGF5S in isolated primary/secondary hair follicle dermal papilla cells; qPCR for downstream gene expression; FGFR1 expression confirmed by immunostaining\",\n      \"journal\": \"Gene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — adenoviral gain-of-function with downstream gene readouts, single lab, consistent with prior mechanistic data\",\n      \"pmids\": [\"26390813\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"FGF5 promotes osteosarcoma cell proliferation through activation of the MAPK signaling pathway: CRISPR/Cas9 knockout of FGF5 reduces MAPK pathway protein levels and inhibits proliferation; recombinant FGF5 addition restores MAPK activity and promotes proliferation while inhibiting apoptosis.\",\n      \"method\": \"CRISPR/Cas9 FGF5 knockout; recombinant FGF5 treatment; Western blot for MAPK pathway proteins; CCK-8 proliferation assay; xenograft nude mouse model\",\n      \"journal\": \"Cancer management and research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO and recombinant protein rescue with pathway readout, single lab, in vitro and in vivo\",\n      \"pmids\": [\"31372048\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"FGF5 inhibits ERK1/2 MAPK activity in Schwann cells while promoting rapid Schwann cell migration and adhesion via upregulation of N-cadherin. FGF5 is strongly upregulated in Schwann cells of the distal mouse sciatic nerve following injury; FGFR1 and FGFR2 are the predominant FGF5 receptors expressed in peripheral nerve Schwann cells.\",\n      \"method\": \"Microarray and mRNA sequencing of injured sciatic nerve; RT-PCR, qPCR, Western blotting, immunostaining; recombinant FGF5 treatment of primary rat Schwann cells; ERK1/2 phosphorylation assay; migration assay; N-cadherin expression assay\",\n      \"journal\": \"Frontiers in cellular neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (expression profiling, Western, migration assay, ERK assay), single lab\",\n      \"pmids\": [\"32848626\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"In FGF5-knockout sheep, the downstream signaling cascade of FGF5 involves FGFR1 → androgen/AR → Wnt/β-catenin → Shh/Gli2 → c-MYC → keratins, and crosstalk between androgen and Wnt/β-catenin signaling contributes to increased fine-wool and active hair-follicle density when FGF5 is absent.\",\n      \"method\": \"CRISPR/Cas9 FGF5 KO in Dorper sheep; qPCR for FGF5 mRNA; H&E and immunohistochemistry; Western blot for pathway components; pathway inhibitor/activator experiments\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO with pathway analysis using multiple methods, single lab\",\n      \"pmids\": [\"32472005\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"RNA aptamers selected against human FGF5 bind FGF5 with high affinity and specificity (Kd = 0.7 nM for F5f1; Kd = 0.118 nM for truncated F5f1_56) and inhibit FGF5-induced cell proliferation without inhibiting FGF2-induced proliferation, establishing that FGF5 receptor-binding activity drives its mitogenic effect.\",\n      \"method\": \"SELEX (aptamer selection); surface plasmon resonance binding assay; FGF5-induced cell proliferation inhibition assay; cross-reactivity testing with FGF1, FGF2, FGF4, FGF6, FGFR1\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — in vitro binding (SPR) and functional cell proliferation assay, single lab, two orthogonal methods\",\n      \"pmids\": [\"33536494\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"FGF5 gene expression in differentiated RPE cells is controlled by a proximal promoter/enhancer active between sequences -314 and +48 (not cell-context dependent), and a silencer element (-1256/-883) active only in differentiated RPE cells. Specific nuclear proteins from differentiated (but not proliferating) RPE cells bind to two small distal promoter regions (-1195/-1173 and -984/-967), suggesting differentiation-specific transcriptional repression of FGF5.\",\n      \"method\": \"Transient transfection of FGF5 promoter/luciferase deletion constructs in proliferating vs. differentiated RPE cells; gel mobility shift assays with differentiated/proliferating nuclear extracts\",\n      \"journal\": \"Experimental eye research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — promoter deletion analysis plus EMSA for protein binding, single lab, two orthogonal methods\",\n      \"pmids\": [\"9733582\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"FGF5 overexpression in cardiomyocytes reduces LPS-induced pyroptosis and oxidative stress by inhibiting CaMKII/NFκB signaling: FGF5 overexpression decreases p-CaMKII, p-NFκB, NLRP3, caspase-1, IL-1β and IL-18 levels; the CaMKII inhibitor KN93 recapitulates FGF5's protective effects.\",\n      \"method\": \"Adenovirus-mediated FGF5 overexpression in vivo (mouse LPS model) and in vitro (cardiomyocytes); echocardiography; Western blot for CaMKII, NFκB, NLRP3, caspase-1, IL-1β, IL-18; KN93 pharmacological inhibition\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo and in vitro gain-of-function plus pharmacological inhibitor validation, single lab\",\n      \"pmids\": [\"36368152\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"FGF5 overexpression protects endothelial cells from LPS-induced pyroptosis via activation of AKT signaling: FGF5 overexpression activates AKT, and the AKT inhibitor MK2206 abolishes FGF5's protective effect in HUVECs exposed to LPS.\",\n      \"method\": \"FGF5 overexpression in mouse ALI model and HUVECs; pyroptosis assay; Western blot for AKT; pharmacological inhibition with MK2206\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro/in vivo gain-of-function with pathway inhibitor rescue, single lab\",\n      \"pmids\": [\"36244113\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"FGF5 promoter methylation in esophageal squamous cell carcinoma represses FGF5 expression. Cisplatin treatment induces FGF5 expression in unmethylated cell lines but not methylated ones; exogenous FGF5 overexpression in a methylated cell line confers resistance to cisplatin, indicating FGF5 expression modulates chemotherapy response.\",\n      \"method\": \"Bisulfite pyrosequencing for methylation; qPCR/Western blot for FGF5 expression; cisplatin treatment of cell lines with varying methylation status; FGF5 overexpression in methylated cell line; clonogenic survival assay\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — methylation-expression correlation confirmed by functional overexpression experiment, single lab, multiple methods\",\n      \"pmids\": [\"31527639\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"FGF2 and FGF5 intrinsic to human aortic endothelial cells (HAECs) promote angiogenesis: siRNA knockdown of FGF2 and FGF5 significantly attenuates VEGF-A-stimulated vascular sprouting from HAECs (but less so from HUVECs), demonstrating an autocrine/paracrine angiogenic role for FGF5 in aortic endothelial cells.\",\n      \"method\": \"3D microfluidic angiogenesis system; siRNA knockdown of FGF2 and FGF5 in HAECs and HUVECs; quantification of vascular sprouting; qPCR for FGF2/FGF5 expression\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional RNAi knockdown in 3D system with phenotypic quantification, single lab\",\n      \"pmids\": [\"27357248\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"FGF5 misexpression in the developing chick limb (via RCAS retroviral vector) severely inhibits mature myocyte formation (reduced MyoD and myosin heavy chain expression) and simultaneously stimulates proliferation and expansion of tenascin-expressing connective tissue fibroblasts and perichondrial cells, as measured by BrdU incorporation.\",\n      \"method\": \"RCAS retroviral overexpression of human FGF5 in chick embryo hindlimb; immunostaining for MyoD, myosin heavy chain, tenascin; BrdU pulse labeling for proliferation; histological analysis\",\n      \"journal\": \"Developmental dynamics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo gain-of-function with multiple immunostaining and proliferation readouts, single lab\",\n      \"pmids\": [\"11066093\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Adeno-associated virus-mediated FGF-5 delivery to the subretinal space of P23H and S334ter transgenic rats rescues photoreceptors from cell death. Post-injection, FGF-5 protein localizes to inner and outer segments of photoreceptors, and FGFR1 and FGFR2 are upregulated in these regions, suggesting rescue is mediated by receptor tyrosine kinase signaling in photoreceptors.\",\n      \"method\": \"Subretinal AAV injection; morphological and ERG functional analysis; immunocytochemistry for FGF-5, FGFR1, FGFR2 localization\",\n      \"journal\": \"Molecular therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo gene delivery with functional and morphological rescue plus receptor localization, single lab\",\n      \"pmids\": [\"11319911\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"FGF5 overexpression in human melanoma cells increases clonogenicity and invasion (but not short-term growth) in vitro, and enhances tumor growth, proliferation index, and angiogenesis in vivo. These effects are associated with increased signaling along the MAPK and NFAT axes but no effect on STAT3 signaling. Silencing FGF5 in high-FGF5 melanoma cells has opposite effects.\",\n      \"method\": \"FGF5 overexpression and siRNA silencing in melanoma cell lines; clonogenicity and invasion assays; xenograft in vivo model; Ki-67 and apoptosis assays; signaling pathway Western blots; tissue microarray immunohistochemistry\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — bidirectional manipulation (OE + KD) with multiple functional readouts and pathway analysis, single lab\",\n      \"pmids\": [\"29152117\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"FGF5 editing in sheep decreases cortisol concentration in skin, activates antioxidant enzyme GSH-Px, and modulates Wnt signaling pathway components (Rspondins as agonists, Notum as antagonist) in hair follicle regeneration, promoting secondary hair follicle development and fine wool growth.\",\n      \"method\": \"CRISPR/Cas9 FGF5 editing in Dorper sheep; cortisol measurement; GSH-Px activity assay; qPCR and Western blot for Wnt pathway components; histological analysis of hair follicle density\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo genetic KO with multiple molecular pathway readouts, single lab\",\n      \"pmids\": [\"38891117\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"FGF5 knockout (combined with MSTN Del73C mutation) in sheep activates FOSL1 via the MEK-ERK-FOSL1 axis; activated FOSL1 promotes skeletal muscle satellite cell proliferation and inhibits myogenic differentiation by suppressing MyoD1 expression, resulting in smaller myotubes; activated ERK1/2 also inhibits secondary myotube fusion via Ca2+-dependent CaMKII activation.\",\n      \"method\": \"CRISPR/Cas9 dual-gene edited sheep (MSTN Del73C + FGF5 KO); Western blot for MEK-ERK-FOSL1 pathway; MyoD1 expression analysis; myotube morphology; CaMKII pathway analysis; F0 and F1 phenotyping\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo genetic model with multiple downstream pathway readouts, though FGF5 and MSTN effects are confounded by dual-gene editing\",\n      \"pmids\": [\"39365728\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"FGF5 overexpression suppresses ferroptosis in renal tubular epithelial cells subjected to ischemia-reperfusion-like injury by activating mitophagy, reducing oxidative stress and inflammatory responses.\",\n      \"method\": \"FGF5 overexpression in NRK-52E and HK-2 cells; cell viability assay; oxidative stress markers; inflammatory cytokine assay; mitophagy assessment; ferroptosis markers\",\n      \"journal\": \"Journal of molecular histology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, in vitro only, mechanistic link between FGF5, mitophagy, and ferroptosis established by overexpression alone without definitive mechanistic dissection\",\n      \"pmids\": [\"40913740\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"The FGF5 oncogene was mapped to human chromosome 4 by PCR-based somatic cell hybrid analysis.\",\n      \"method\": \"PCR amplification of FGF5 sequences from somatic cell hybrid DNAs containing defined human chromosomes\",\n      \"journal\": \"BioTechniques\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct PCR-based chromosomal assignment, clear single-method result\",\n      \"pmids\": [\"2317376\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"FGF5 is a secreted signaling protein that acts as a negative regulator of the mammalian hair growth cycle by inhibiting anagen progression and inducing the anagen-to-catagen transition via its predominant high-affinity receptor FGFR1 IIIc, which activates MAPK signaling; its alternatively spliced short form (FGF5S) functions as a partial antagonist that competes for FGFR1 binding and suppresses FGF5-induced catagen; beyond hair follicles, FGF5 also regulates astroglial differentiation and blood-brain barrier integrity, promotes Schwann cell migration and adhesion via N-cadherin upregulation while inhibiting ERK activity, stimulates cardiac myocyte hypertrophy and cell cycle re-entry, and exerts pro-tumorigenic autocrine/paracrine effects through MAPK and NFAT signaling in glioblastoma and melanoma.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"FGF5 is a secreted member of the fibroblast growth factor family that acts as a key negative regulator of the mammalian hair growth cycle, inhibiting hair elongation and driving the anagen-to-catagen transition [#0, #1]. Genetic loss of Fgf5 in mice (null allele and the spontaneous angora mutation) and recessive loss-of-function mutations in human FGF5 (causing trichomegaly) produce abnormally long hair, while exogenous FGF5 induces follicle regression in human and mouse follicle organ culture and depilated-skin models, establishing FGF5 as a direct catagen inducer [#0, #4, #13]. FGF5 signals predominantly through the IIIc splice variant of FGFR1, activating the MAPK/MEK-ERK pathway to drive proliferation; gain-of-function receptor expression, dominant-negative FGFR1 IIIc, FGFR/MEK inhibitors, and FGF5-specific RNA aptamers all converge on receptor-binding-dependent mitogenesis [#7, #12, #18]. An alternatively spliced short form, FGF5S, which lacks exon 2, binds FGFR1 and acts as a partial antagonist: it suppresses FGF5-induced receptor tyrosine phosphorylation, blocks FGF5's catagen-promoting activity in vivo, and reverses FGF5-driven changes in dermal papilla anagen/catagen gene programs (IGF-1, versican, noggin, BMP4) [#2, #4, #14]. In the absence of FGF5, hair-follicle programs are de-repressed through an FGFR1→androgen/AR→Wnt/β-catenin→Shh/Gli2→c-MYC→keratin cascade, promoting secondary follicle density and fine-wool growth [#17, #27]. Beyond the follicle, FGF5 exerts mitogenic and pro-survival autocrine/paracrine effects in glioblastoma, melanoma, and osteosarcoma via MAPK (and NFAT) signaling [#12, #15, #26], regulates astroglial GFAP expression and blood-brain-barrier integrity [#9], promotes Schwann cell migration and adhesion via N-cadherin while inhibiting ERK [#16], and drives cardiac myocyte hypertrophy and cell-cycle re-entry [#11].\",\n  \"teleology\": [\n    {\n      \"year\": 1988,\n      \"claim\": \"Establishing that FGF5 is a bona fide secreted FGF-family protein with transforming potential defined its molecular identity and oncogenic capacity.\",\n      \"evidence\": \"cDNA cloning, sequence homology analysis, and NIH 3T3 transformation assay\",\n      \"pmids\": [\"3211147\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor and physiological function not yet defined\", \"Mechanism of transformation beyond enhancer-driven overexpression not characterized\"]\n    },\n    {\n      \"year\": 1990,\n      \"claim\": \"Mapping FGF5 to human chromosome 4 anchored the gene physically, enabling later genetic disease association.\",\n      \"evidence\": \"PCR-based somatic cell hybrid chromosomal assignment\",\n      \"pmids\": [\"2317376\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No functional consequence established\", \"No disease locus linkage at this stage\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Loss-of-function genetics answered what FGF5 does physiologically, revealing it as an inhibitor of hair elongation that controls the anagen-to-catagen transition.\",\n      \"evidence\": \"Gene targeting (null allele), complementation with the spontaneous angora mutant, and in situ hybridization in hair follicles\",\n      \"pmids\": [\"7923352\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor mediating the effect not identified\", \"Downstream signaling in follicle not defined\", \"Source cell type of active FGF5 unclear\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Discovery and characterization of the exon-2-skipped short form FGF5S established a built-in antagonistic regulator that competes for FGFR1 and dampens FGF5 signaling.\",\n      \"evidence\": \"cDNA cloning, RT-PCR, FGFR1 competitive binding, tyrosine phosphorylation assay, and PC12 differentiation assay; isoform-specific immunohistochemistry localized the two products to distinct skin compartments\",\n      \"pmids\": [\"9786939\", \"8611621\", \"9856803\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of partial antagonism not resolved\", \"Relative in vivo abundance and regulation of splicing not quantified\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Secretion polarity and promoter dissection addressed how FGF5 production and trafficking are regulated, showing basolateral vectorial secretion and differentiation-specific transcriptional repression.\",\n      \"evidence\": \"Polarized ARPE-19 conditioned-media immunoblot; FGF5 promoter/luciferase deletion constructs and EMSA in proliferating vs differentiated RPE cells\",\n      \"pmids\": [\"9856785\", \"9733582\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Identity of the silencer-binding nuclear proteins unknown\", \"Generalizability of basolateral secretion beyond RPE untested\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Direct protein injection confirmed the dual-mode model, showing full-length FGF5 induces catagen while FGF5S blocks that activity in vivo.\",\n      \"evidence\": \"Subcutaneous recombinant FGF5/FGF5S injection in depilated mice with histological follicle staging\",\n      \"pmids\": [\"10692103\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular signaling in follicle not measured in this assay\", \"Receptor identity not directly tested here\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Receptor-reconstitution experiments identified FGFR1 IIIc and the MEK/MAPK cascade as the route for FGF5-driven proliferation.\",\n      \"evidence\": \"Stable FGFR-1 IIIc transfection of unresponsive TAKA-1 cells, proliferation and MAPK assays, and PD98059 MEK inhibition; concurrent denervation studies linked FGF5 to Schwann cell biology\",\n      \"pmids\": [\"11876253\", \"11598998\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Contribution of other FGFRs not excluded\", \"Co-receptor/heparan requirements not addressed\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Knockout epistasis extended FGF5 function beyond hair to CNS, showing roles in astroglial GFAP expression and blood-brain-barrier integrity, and a receptor-binding peptide validated the FGFR-binding region as the functional determinant.\",\n      \"evidence\": \"Single/double FGF2-FGF5 mutant mice with GFAP staining, EM of endfeet, albumin extravasation, tight-junction immunoblot and astrocyte rescue; FGF5-derived decapeptide P3 competition and in vivo follicle assays\",\n      \"pmids\": [\"12878680\", \"14502567\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct cellular target of FGF5 in CNS vasculature not pinpointed\", \"Redundancy with FGF2 complicates FGF5-specific attribution\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Gain-of-function in myocardium revealed a direct hypertrophic and cell-cycle re-entry effect of FGF5 distinct from angiogenesis.\",\n      \"evidence\": \"Intracoronary AdvFGF-5 in hibernating swine with wall-thickening, myocyte diameter, Ki-67 and phospho-histone H3 measurements\",\n      \"pmids\": [\"15761196\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor/pathway mediating cardiac effect not identified\", \"Single large-animal model\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Autocrine/paracrine FGF5-FGFR1 IIIc signaling was established as a pro-tumorigenic axis in glioblastoma, generalizing the receptor mechanism to cancer.\",\n      \"evidence\": \"siRNA knockdown, recombinant FGF5, dominant-negative FGFR1 IIIc, FGFR inhibitors in GBM cells, plus HUVEC angiogenesis assays\",\n      \"pmids\": [\"18362893\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Driver mutations or amplification status not addressed\", \"Relative autocrine vs paracrine contribution in tumors not quantified\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Subsequent cancer and vascular studies extended the MAPK/NFAT mitogenic axis to melanoma, osteosarcoma, and endothelial angiogenesis, and tied FGF5 expression to epigenetic regulation and chemoresistance.\",\n      \"evidence\": \"siRNA in aortic endothelial 3D sprouting; bidirectional manipulation in melanoma with MAPK/NFAT readouts; CRISPR KO/recombinant rescue with MAPK readout and xenograft in osteosarcoma; promoter methylation and cisplatin response in esophageal carcinoma\",\n      \"pmids\": [\"27357248\", \"29152117\", \"31372048\", \"31527639\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor specificity not uniformly tested across these contexts\", \"Whether NFAT activation is FGFR1-dependent unresolved\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Human genetics and organ culture confirmed FGF5 as a direct catagen inducer in humans and linked its loss to a Mendelian phenotype.\",\n      \"evidence\": \"Whole-exome sequencing and homozygosity mapping in trichomegaly families plus human hair-follicle organ culture with recombinant FGF5\",\n      \"pmids\": [\"24989505\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor mediating human follicle regression not directly tested\", \"Genotype-phenotype range across families incompletely defined\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Livestock knockout and Schwann-cell studies dissected the de-repressed signaling cascades downstream of FGF5 loss and refined its receptor usage and ERK effects in nerve.\",\n      \"evidence\": \"CRISPR FGF5 KO sheep with FGFR1→AR→Wnt/β-catenin→Shh/Gli2→c-MYC→keratin pathway analysis; injured-nerve profiling, recombinant FGF5 on Schwann cells with ERK, migration, and N-cadherin assays\",\n      \"pmids\": [\"32472005\", \"32848626\", \"26390813\", \"38891117\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct versus indirect engagement of each cascade node not resolved\", \"Context-dependent ERK inhibition vs activation by FGF5 unexplained\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Overexpression studies expanded FGF5 into cytoprotective signaling, implicating CaMKII/NFκB and AKT pathways in protection from pyroptosis and oxidative stress.\",\n      \"evidence\": \"Adenoviral FGF5 overexpression in cardiomyocyte and endothelial LPS injury models with CaMKII/NFκB and AKT pathway readouts and KN93/MK2206 inhibitors\",\n      \"pmids\": [\"36368152\", \"36244113\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor linking FGF5 to AKT/CaMKII not identified\", \"Physiological relevance beyond overexpression unestablished\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Dual-gene-edited sheep linked FGF5 loss to skeletal muscle satellite cell regulation through a MEK-ERK-FOSL1-MyoD1 axis.\",\n      \"evidence\": \"CRISPR MSTN Del73C + FGF5 KO sheep with MEK-ERK-FOSL1, MyoD1, and CaMKII pathway analysis and myotube phenotyping\",\n      \"pmids\": [\"39365728\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"FGF5 and MSTN effects confounded by dual editing\", \"FGF5-specific contribution to the muscle phenotype not isolated\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unresolved how FGF5 switches between mitogenic, pro-survival, and ERK-inhibitory outputs across tissues, and which receptor/co-receptor configurations and FGF5S balance dictate context-specific signaling.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No structural model of FGF5/FGF5S-FGFR1 IIIc complex\", \"Mechanistic basis for opposite ERK effects across cell types unknown\", \"In vivo stoichiometry of FGF5 vs FGF5S not quantified\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [2, 7, 12, 18]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [2, 4, 14]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [1, 6]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [7, 12, 15]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [0, 13, 24]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [12, 26, 13]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"FGFR1\", \"FGFR2\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"tie","faith_supported":6,"faith_total":6,"faith_pct":100.0}}